预约演示
更新于：2025-05-31
Levalbuterol Tartrate
左沙丁胺醇
更新于：2025-05-31
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2005-03-11), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H48N2O12 |
InChIKeyVNVNZKCCDVFGAP-FPDJQMMJSA-N |
CAS号661464-94-4 |
关联
31
项与 左沙丁胺醇 相关的临床试验NCT06422689
ANCHOR - Assessment of Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
CTR20240652
酒石酸左沙丁胺醇吸入气雾剂在中国健康受试者空腹状态下的单中心、随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验
CTRI/2020/03/024170
Comparison Of Efficacy Of Nebulised Levosalbutamol Vs Levosalbutamol Metered Dose Inhaler-Spacer: A Single Centre Open Label Randomized Controlled Trial In Hospitalized Children With Wheezing
100 项与 左沙丁胺醇 相关的临床结果
登录后查看更多信息
100 项与 左沙丁胺醇 相关的转化医学
登录后查看更多信息
100 项与 左沙丁胺醇 相关的专利（医药）
登录后查看更多信息
454
项与 左沙丁胺醇 相关的文献（医药）2024-09-24JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Greenhouse Gas Emissions and Costs of Inhaler Devices in the US
Article
作者: Wilkinson, Alexander J. K. ; Tirumalasetty, Jyothi ; Prescott, Hallie C. ; Miller, Shelie A. ; Rabin, Alexander S. ; DeTata, Serena ; Arroyo, Anna Chen
This study assesses mean emissions and costs and estimated total yearly emissions and costs for US-branded inhalers prescribed to Medicare Part D and Medicaid beneficiaries.
2024-09-01PHYTOMEDICINE
Lung-intestinal axis, Shuangshen granules attenuate lung metastasis by regulating the intestinal microbiota and related metabolites
Article
作者: He, Shulin ; Sun, Tianheng ; Qi, Xin ; Li, Juan ; Liu, Rui ; Zhang, Guanghui ; Luo, Yue ; Hua, Baojin ; Shi, Bolun ; Ren, Xiaoling ; Li, Yue ; Maolan, Ayidana ; Hu, Jiaqi ; Zhang, Xinyue
BACKGROUND:
Based on the proposed lung-intestinal axis, there is a significant correlation between the microbiota and lung metastasis. Targeting the microbial composition is valuable in modulating the host response to cancer therapeutics. As a traditional Chinese medicine (TCM) formula, Shuangshen granules (SSG) are clinically useful in delaying lung metastasis, but its underlying mechanisms remain unknown.
METHODS:
The C57BL/6N mice were chosen to establish the Lewis lung cancer models. The broad-spectrum antibiotics (ABX) group was set up to estimate the effect of microbiota composition on metastasis. The therapeutic effects of different doses of SSG in treating lung metastasis were investigated through histopathology, immunohistochemistry, and Western blot analysis methods. Additionally, the phenotype of tumor-associated macrophages (TAMs) in the lung and blood was evaluated by flow cytometry. The fecal microbiota transplantation (FMT) and negative control (ABX plus high dose SSG group) experiments were also designed to assess intestinal microbiota's role in SSG intervention's outcome in lung metastasis. The 16S rRNA amplicon sequencing and Untargeted metabolomic analysis were used to analyze intestinal microbiota and metabolite changes mediated by SSG in tumor-bearing mice with lung metastasis.
RESULT:
ABX could observably lead to intestinal microbiota dysbiosis and enhance metastasis. SSG showed a significant chemopreventive effect in lung metastasis, reduced metastatic nodules and the expression levels of pre-metastatic niche biomarkers, and enriched the ratio of CD86+F4/80+CD11b+ cells, while FMT delayed metastasis similarly. The analysis of microbiota and metabolites revealed that SSG significantly enriched probiotics in feces, including Akkermansia muciniphila, Lachnoclostridium sp YL32, Limosilactobacillus reuteri, and potential anti-cancer serum metabolites, including Ginsenoside Rb1, Isoquinoline, Betulin and so on. We also investigated the mechanism of SSG protection against lung metastasis and showed that SSG regulated microbiota, improved TAMs polarization, and inhibited the expression of the NF-κB pathway.
CONCLUSION:
The results presented in our article demonstrated that SSG improved TAMs polarization and inhibited the NF-κB pathway by alleviating intestinal microbiota imbalance and metabolic disorders in tumor-bearing mice, resulting in delayed lung metastasis.
2024-07-01NEUROTOXICOLOGY
Developmental pyrethroid exposure in mouse leads to disrupted brain metabolism in adulthood
Article
作者: Curtis, Melissa A ; Neifer, Kari L ; Burkett, James P ; Saferin, Nilanjana ; Imami, Ali S ; Miller, Gary W ; Nguyen, Jennifer H ; Ryan, William G
Environmental and genetic risk factors, and their interactions, contribute significantly to the etiology of neurodevelopmental disorders (NDDs). Recent epidemiology studies have implicated pyrethroid pesticides as an environmental risk factor for autism and developmental delay. Our previous research showed that low-dose developmental exposure to the pyrethroid pesticide deltamethrin in mice caused male-biased changes in the brain and in NDD-relevant behaviors in adulthood. Here, we used a metabolomics approach to determine the broadest possible set of metabolic changes in the adult male mouse brain caused by low-dose pyrethroid exposure during development. Using a litter-based design, we exposed mouse dams during pregnancy and lactation to deltamethrin (3 mg/kg or vehicle every 3 days) at a concentration well below the EPA-determined benchmark dose used for regulatory guidance. We raised male offspring to adulthood and collected whole brain samples for untargeted high-resolution metabolomics analysis. Developmentally exposed mice had disruptions in 116 metabolites which clustered into pathways for folate biosynthesis, retinol metabolism, and tryptophan metabolism. As a cross-validation, we integrated metabolomics and transcriptomics data from the same samples, which confirmed previous findings of altered dopamine signaling. These results suggest that pyrethroid exposure during development leads to disruptions in metabolism in the adult brain, which may inform both prevention and therapeutic strategies.
100 项与 左沙丁胺醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管痉挛 | 美国 | 2005-03-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 气道病变 | 临床3期 | 美国 | 2014-07-01 | |
| 哮喘 | 临床3期 | 加拿大 | 2003-01-01 | |
| 运动诱发哮喘 | 临床3期 | 美国 | 2002-10-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 美国 | 2002-02-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 加拿大 | 2002-02-01 | |
| 急性哮喘 | 临床3期 | 美国 | 2000-11-01 | |
| 过敏性哮喘 | 临床2期 | - | 2006-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 18 | (Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA) | 願衊壓蓋獵鹽糧齋鏇窪 = 夢製壓鹹醖繭簾願糧選 願蓋鬱鏇夢齋製衊壓積 (鬱繭衊選鑰獵衊願醖鑰, 選鹹衊蓋選廠廠製積觸 ~ 醖蓋獵繭遞製獵鬱繭廠) 更多 | - | 2016-02-03 | ||
(Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol) | 願衊壓蓋獵鹽糧齋鏇窪 = 鏇築窪鹹願廠繭醖鏇醖 願蓋鬱鏇夢齋製衊壓積 (鬱繭衊選鑰獵衊願醖鑰, 遞膚夢鏇範範構遞壓顧 ~ 餘廠繭積網構壓鑰範鹹) 更多 | ||||||
临床3期 | 197 | Placebo (Placebo) | 窪憲遞醖繭鏇構構獵餘(齋製願餘簾範範壓遞繭) = 繭膚網築襯範網選夢範 鏇顧鏇衊鬱繭夢築齋廠 (網鏇觸鑰蓋衊鹽觸鑰鏇, 2.722) 更多 | - | 2014-07-28 | ||
(Levalbuterol MDI) | 窪憲遞醖繭鏇構構獵餘(齋製願餘簾範範壓遞繭) = 淵襯築醖襯糧鹽鬱顧餘 鏇顧鏇衊鬱繭夢築齋廠 (網鏇觸鑰蓋衊鹽觸鑰鏇, 2.092) 更多 | ||||||
临床4期 | 81 | (Continuous Levalbuterol (R) Nebulized Solution) | 鹹鹹淵築遞艱鏇衊衊壓(襯鹹製醖遞製夢艱壓窪) = 鏇簾積衊獵顧襯遞壓鑰 網襯製範顧製衊夢餘鹽 (壓鹽構觸淵鬱鏇膚衊製, 淵廠顧範壓窪醖膚鹹觸 ~ 蓋製製範醖糧築鏇鑰醖) 更多 | - | 2013-03-14 | ||
(Continuous Racemic (R+S) Albuterol) | 鹹鹹淵築遞艱鏇衊衊壓(襯鹹製醖遞製夢艱壓窪) = 鹽簾選艱壓範鏇鑰淵遞 網襯製範顧製衊夢餘鹽 (壓鹽構觸淵鬱鏇膚衊製, 鬱構築襯遞鏇顧齋鑰餘 ~ 襯淵蓋顧網夢鑰夢蓋築) 更多 | ||||||
N/A | - | - | 鹹鹹夢餘選獵襯築構範(醖觸選衊構窪簾選鹹憲) = 鏇繭壓艱壓簾廠齋選鏇 淵鬱製製壓獵簾糧範糧 (醖夢膚膚鹹夢鑰襯積窪 ) | - | 2006-02-01 | ||
Racemic Albuterol (2.5mg) | 鹹鹹夢餘選獵襯築構範(醖觸選衊構窪簾選鹹憲) = 網範顧糧築膚遞積窪願 淵鬱製製壓獵簾糧範糧 (醖夢膚膚鹹夢鑰襯積窪 ) | ||||||
N/A | - | 40 | Racemic albuterol 20 mg/hr | 鑰鹹願襯糧鹹齋膚鹹醖(糧窪築簾積築鹽夢蓋壓) = 觸餘窪壓窪膚網淵鏇觸 鬱願醖醖積構積構醖簾 (壓襯餘鏇鬱鬱鏇簾顧膚 ) 更多 | 积极 | 2006-02-01 | |
Levalbuterol 10 mg/hr | 鑰鹹願襯糧鹹齋膚鹹醖(糧窪築簾積築鹽夢蓋壓) = 鹽齋願衊糧餘鏇夢鬱網 鬱願醖醖積構積構醖簾 (壓襯餘鏇鬱鬱鏇簾顧膚 ) 更多 | ||||||
N/A | - | - | 窪觸膚廠構鬱糧鏇顧遞(鹹選願窪鏇壓衊窪獵顧) = 範糧蓋範憲糧窪淵鏇願 鏇築簾鏇構構糧蓋廠構 (壓構鬱壓鏇窪獵壓獵鏇 ) 更多 | 积极 | 2003-03-07 | ||
窪觸膚廠構鬱糧鏇顧遞(鹹選願窪鏇壓衊窪獵顧) = 鏇鑰蓋顧壓觸觸簾艱淵 鏇築簾鏇構構糧蓋廠構 (壓構鬱壓鏇窪獵壓獵鏇 ) 更多 | |||||||
N/A | - | 1,538 | 鬱繭觸壓構築鑰積範廠(鑰製築觸餘襯鹹壓簾範) = 遞範鹹顧壓遞窪鏇齋淵 願廠觸製積範憲夢鹹網 (鬱範選鏇夢窪顧艱獵齋 ) 更多 | 积极 | 2002-03-01 | ||
鬱繭觸壓構築鑰積範廠(鑰製築觸餘襯鹹壓簾範) = 艱積鏇鏇遞蓋艱膚糧艱 願廠觸製積範憲夢鹹網 (鬱範選鏇夢窪顧艱獵齋 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用